Evercore ISI Group Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 92.2%

Neg 0% Neu 0% Pos 92.2%

Evercore ISI Group analyst Cory Kasimov maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $110 to $120.